-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Oscar Health, Raises Price Target to $20

Benzinga·05/07/2026 23:02:18
Listen to the news
UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $15 to $20.